ViaCyte Overview

  • Founded

  • 1999

Founded
  • Status

  • Private

  • Employees

  • 128

Employees
  • Latest Deal Type

  • Series D

  • Latest Deal Amount

  • $53.9M

  • Investors

  • 31

ViaCyte General Information

Description

Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and disorders. The company's therapies are based on two major technological advances including cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation, enabling healthcare institutions to reduce the risk of hypoglycemia and diabetes-related complications.

Contact Information

Website
www.viacyte.com
Formerly Known As
Novocell, CyThera
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 5580 Morehouse Drive
  • Suite 100
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

ViaCyte Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ViaCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
26. Later Stage VC (Series D) 09-Jun-2021 $53.9M 00000 00000 Completed Clinical Trials - Phase 2
25. Later Stage VC (Series D3) 04-Jul-2020 0000 00000 00000 Completed Generating Revenue
24. Secondary Transaction - Private 00000 Completed Clinical Trials - General
23. Later Stage VC (Series D2) 26-May-2020 000.00 00000 00000 Completed Clinical Trials - General
22. Later Stage VC 25-Sep-2018 0000 00000 Completed Clinical Trials - General
21. Grant 17-Apr-2018 00.00 00000 Completed Clinical Trials - General
20. Grant 15-Dec-2017 00.00 00000 Completed Clinical Trials - General
19. Later Stage VC 22-May-2017 0000 00000 Completed Clinical Trials - General
18. Grant 01-Jan-2017 $23.1M $104M Completed Clinical Trials - General
17. Grant 11-Sep-2014 $16.6M $104M Completed Clinical Trials - General
To view ViaCyte’s complete valuation and funding history, request access »

ViaCyte Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D-4A 00,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series D-4 000,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series D-3A 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series D-3 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D1 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00 00 00 00 00 0.000
Series C 00,000,000 00.000000 00 00 00 00 00 0.000
Series B 27,876,992 $0.001000 8% $1 $1 1x $1 3.89%
Series A 8,020,005 $0.001000 8% $1 $1 1x $1 1.12%
To view ViaCyte’s complete cap table history, request access »

ViaCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and
Drug Discovery
San Diego, CA
128 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00

0.0. 0

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000000000000
Sunrise, FL
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViaCyte Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sernova Corporation London, Canada 00 000.00 00000000 000.00
0.0. 0000 0000 Formerly VC-backed Sunrise, FL 00 000.00 000000000 000.00
00000000000 Venture Capital-Backed San Diego, CA 0 000.00 00000000000 000.00
0000000 0000 00000 Corporation Carlsbad, CA 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed Boulder, CO 00 00000 000000000 00000
You’re viewing 5 of 38 competitors. Get the full list »

ViaCyte Patents

  • 505

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 34

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

ViaCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3069519-A1 Universal donor cells and related methods Pending 12-Jul-2017 0000000000
US-20190015487-A1 Universal donor cells and related methods Granted 12-Jul-2017 0000000000
US-20190255159-A1 Universal donor cells and related methods Pending 12-Jul-2017 0000000000
EP-3652304-A4 Universal donor cells and related methods Pending 12-Jul-2017 0000000000 0
JP-2020526224-A Universal donor cells and related methods Pending 12-Jul-2017 C12N5/0676 0
To view ViaCyte’s complete patent history, request access »

ViaCyte Executive Team (19)

Name Title Board Seat Contact Info
Alyssa Levin Chief Financial Officer
Steve White Chief Technology Officer
Mark Zimmerman Ph.D Senior Vice President of Business Development and Operations
Howard Foyt Ph.D Senior Medical Advisor & Vice President
Manasi Sinha Jaiman Vice President, Clinical Development
You’re viewing 5 of 19 executive team members. Get the full list »

ViaCyte Board Members (16)

Name Representing Role Since
Adam Koppel Ph.D Bain Capital Board Member 000 0000
Amir Zamani MD Self Board Member 000 0000
Asish Xavier Ph.D Self Board Member 000 0000
Fred Middleton Sanderling Ventures Board Member 000 0000
Heath Lukatch Ph.D Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

ViaCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViaCyte Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adage Capital Management Hedge Fund Minority 000 0000 000000 0
Asymmetry Ventures Venture Capital Minority 000 0000 000000 0
The Invus Group PE/Buyout Minority 000 0000 000000 0
ARTIS Ventures Venture Capital Minority 000 0000 000000 0
Bain Capital Life Sciences Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 31 investors. Get the full list »

ViaCyte Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 (0000 18-Dec-2015 0000000000 Biotechnology 0000 0000
To view ViaCyte’s complete acquisitions history, request access »

Ready to get started?

Request a free trial